---
layout: default
title: Sodium Fluoride
parent: 僅模型預測 (L5)
nav_order: 912
evidence_level: L5
indication_count: 10
---

# Sodium Fluoride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using no skill — this is a direct evidence-pack-to-report task governed by the prompt spec itself; the SgTxGNN CLAUDE.md doesn't require any script here, and no coding/debugging is involved.

# Sodium Fluoride: From No Recorded Indication to Epiglottitis

## One-Sentence Summary

Sodium fluoride (DB09325) has no recorded original indication and no market presence in Singapore in the current evidence pack. The TxGNN model predicts it may be effective for **Epiglottitis**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, and the model's own rationale explicitly notes no known mechanistic basis for this link.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no Singapore registration or indication data recorded |
| Predicted New Indication | Epiglottitis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for sodium fluoride. No original indication is recorded in this evidence pack, so no basis exists for evaluating pharmacological continuity between an existing use and epiglottitis.

More importantly, the evidence pack's own repurposing rationale for this candidate states directly: *"No known mechanistic link. Sodium fluoride has no antimicrobial or anti-inflammatory properties that would support treatment of bacterial epiglottitis (commonly caused by H. influenzae), and the absence of MOA data prevents construction of a plausible hypothesis."* This indicates the high TxGNN score (99.92%, rank 1650) likely reflects knowledge-graph topological similarity rather than an underlying pharmacological relationship. The same pattern holds across the other nine predicted indications in this candidate set — all are flagged with "no mechanistic link" and Hold recommendations.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

*(Note: a lower-ranked candidate in this drug's prediction set — laryngitis, rank 7 — did return 5 PubMed records, but on review none support a therapeutic mechanism: three are ¹⁸F-NaF PET/CT imaging case reports for unrelated oncologic staging, one is a diphtheria-toxin cell-culture study, and one is a poultry intestinal-development study. None constitute clinical evidence for laryngitis treatment.)*

## Singapore Market Information

Sodium fluoride has no registered product licenses in Singapore (0 total registrations); no market authorization data is available.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There is no mechanism of action data, no original indication on record, no clinical trial or literature evidence for the top-ranked predicted indication, and the drug is not currently marketed in Singapore. The prediction rationale itself states no known mechanistic link to epiglottitis, indicating this is a pure knowledge-graph score without pharmacological support.

**To proceed, the following is needed:**
- Sodium fluoride's mechanism of action (DG002, High severity — currently blocking rationale analysis)
- TFDA/HSA package insert warnings and contraindications (DG001, Blocking severity — required before any S1 safety screening)
- Confirmation of original approved indication(s), if any, in a comparable market
- Independent literature or preclinical search specifically for antimicrobial/anti-inflammatory activity relevant to epiglottitis, given none was found in this pass
- Given the uniformly weak rationale across all 10 predicted indications for this drug, consider deprioritizing this candidate in favor of higher-evidence drugs in the pipeline
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

